Jun Wu1, Daniel Ryskamp1, Lutz Birnbaumer2,3, Ilya Bezprozvanny1,4. 1. Department of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 2. Neurobiology Laboratory, NIEHS, Research Triangle Park, NC, USA. 3. Institute of Biomedical Research (BIOMED), Catholic University of Argentina, C1107AFF Buenos Aires, Argentina. 4. Laboratory of Molecular Neurodegeneration, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia.
Abstract
BACKGROUND: Huntington disease (HD) is a dominantly inherited neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene. We previously discovered that mutant Huntingtin sensitizes type 1 inositol 1,4,5-trisphosphate receptor (InsP3R1) to InsP3. This causes calcium leakage from the endoplasmic reticulum (ER) and a compensatory increase in neuronal store-operated calcium (nSOC) entry. We previously demonstrated that supranormal nSOC leads to synaptic loss in striatal medium spiny neurons (MSNs) in YAC128 HD mice. OBJECTIVE: We sought to identify calcium channels supporting supranormal nSOC in HD MSNs and to validate these channels as potential therapeutic targets for HD. METHODS: Cortico-striatal cultures were established from wild type and YAC128 HD mice and the density of MSN spines was quantified. The expression of candidate nSOC components was suppressed by RNAi knockdown and by CRISPR/Cas9 knockout. TRPC1 knockout mice were crossed with YAC128 HD mice for evaluation of motor performance in a beamwalk assay. RESULTS: RNAi-mediated knockdown of TRPC1, TRPC6, Orai1, or Orai2, but not other TRPC isoforms or Orai3, rescued the density of YAC128 MSN spines. Knockdown of stromal interaction molecule 1 (STIM1), an ER calcium sensor and nSOC activator, also rescued YAC128 MSN spines. Knockdown of the same targets suppressed supranormal nSOC in YAC128 MSN spines. These channel subunits co-immunoprecipitated with STIM1 and STIM2 in synaptosomal lysates from mouse striata. Crossing YAC128 mice with TRPC1 knockout mice improved motor performance and rescued MSN spines in vitro and in vivo, indicating that inhibition of TRPC1 may serve as a neuroprotective strategy for HD treatment. CONCLUSIONS: TRPC1 channels constitute a potential therapeutic target for treatment of HD.
BACKGROUND:Huntington disease (HD) is a dominantly inherited neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene. We previously discovered that mutant Huntingtin sensitizes type 1 inositol 1,4,5-trisphosphate receptor (InsP3R1) to InsP3. This causes calcium leakage from the endoplasmic reticulum (ER) and a compensatory increase in neuronal store-operated calcium (nSOC) entry. We previously demonstrated that supranormal nSOC leads to synaptic loss in striatal medium spiny neurons (MSNs) in YAC128HDmice. OBJECTIVE: We sought to identify calcium channels supporting supranormal nSOC in HD MSNs and to validate these channels as potential therapeutic targets for HD. METHODS: Cortico-striatal cultures were established from wild type and YAC128HDmice and the density of MSN spines was quantified. The expression of candidate nSOC components was suppressed by RNAi knockdown and by CRISPR/Cas9 knockout. TRPC1 knockout mice were crossed with YAC128HDmice for evaluation of motor performance in a beamwalk assay. RESULTS: RNAi-mediated knockdown of TRPC1, TRPC6, Orai1, or Orai2, but not other TRPC isoforms or Orai3, rescued the density of YAC128MSN spines. Knockdown of stromal interaction molecule 1 (STIM1), an ER calcium sensor and nSOC activator, also rescued YAC128MSN spines. Knockdown of the same targets suppressed supranormal nSOC in YAC128MSN spines. These channel subunits co-immunoprecipitated with STIM1 and STIM2 in synaptosomal lysates from mouse striata. Crossing YAC128mice with TRPC1 knockout mice improved motor performance and rescued MSN spines in vitro and in vivo, indicating that inhibition of TRPC1 may serve as a neuroprotective strategy for HD treatment. CONCLUSIONS:TRPC1 channels constitute a potential therapeutic target for treatment of HD.
Authors: Jana Hartmann; Rosa M Karl; Ryan P D Alexander; Helmuth Adelsberger; Monika S Brill; Charlotta Rühlmann; Anna Ansel; Kenji Sakimura; Yoshihiro Baba; Tomohiro Kurosaki; Thomas Misgeld; Arthur Konnerth Journal: Neuron Date: 2014-05-07 Impact factor: 17.173
Authors: Yousang Gwack; Sonal Srikanth; Masatsugu Oh-Hora; Patrick G Hogan; Edward D Lamperti; Megumi Yamashita; Curtis Gelinas; Daniel S Neems; Yoshiteru Sasaki; Stefan Feske; Murali Prakriya; Klaus Rajewsky; Anjana Rao Journal: Mol Cell Biol Date: 2008-06-30 Impact factor: 4.272
Authors: J P Vonsattel; R H Myers; T J Stevens; R J Ferrante; E D Bird; E P Richardson Journal: J Neuropathol Exp Neurol Date: 1985-11 Impact factor: 3.685
Authors: Elizabeth J Slow; Jeremy van Raamsdonk; Daniel Rogers; Sarah H Coleman; Rona K Graham; Yu Deng; Rosemary Oh; Nagat Bissada; Sazzad M Hossain; Yu-Zhou Yang; Xiao-Jiang Li; Elizabeth M Simpson; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden Journal: Hum Mol Genet Date: 2003-07-01 Impact factor: 6.150
Authors: Jaepyo Jeon; Fan Bu; Guanghua Sun; Jin-Bin Tian; Shun-Ming Ting; Jun Li; Jaroslaw Aronowski; Lutz Birnbaumer; Marc Freichel; Michael X Zhu Journal: Front Cell Dev Biol Date: 2021-01-08
Authors: Daniel Ryskamp; Lili Wu; Jun Wu; Dabin Kim; Gerhard Rammes; Michal Geva; Michael Hayden; Ilya Bezprozvanny Journal: Neurobiol Dis Date: 2018-12-27 Impact factor: 5.996
Authors: Magdalena Czeredys; Vladimir A Vigont; Vasilisa A Boeva; Katsuhiko Mikoshiba; Elena V Kaznacheyeva; Jacek Kuznicki Journal: Front Cell Neurosci Date: 2018-10-26 Impact factor: 5.505